Tandem Diabetes Care (TNDM) Operating Leases (2019 - 2026)

Tandem Diabetes Care (TNDM) has reported Operating Leases for 8 consecutive years, with $136.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 2.28% year-over-year to $136.7 million; the trailing twelve-month figure through Jun 2026 stood at $136.7 million (down 2.28% YoY), and the FY2025 full-year result was $115.0 million, up 8.03% from the prior year.
• Operating Leases rose to $136.7 million in Q2 2026 per TNDM's latest filing, from $133.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $143.8 million in Q1 2025 and bottomed at $106.4 million in Q4 2024.
• Historically, Operating Leases has averaged $131.2 million across 5 years, with a median of $134.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Operating Leases soared 416.36% in 2022, then fell 8.06% in 2023.
• Over 5 years, Operating Leases stood at $123.5 million in 2022, then declined by 8.06% to $113.6 million in 2023, then dropped by 6.3% to $106.4 million in 2024, then rose by 8.03% to $115.0 million in 2025, then rose by 18.88% to $136.7 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $136.7 million, $133.0 million, and $115.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.